# OnCo record nct04956640 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04956640/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04956640", "NCT04956640" ;
  schema:name "Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)"@en ;
  schema:description "A phase 1/2 trial of Olomorasib, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin and Carboplatin in non-small-cell lung cancer, colorectal cancer, endometrial cancer, ovarian cancer, pancreatic ductal adenocarcinoma and biliary tract cancer, run by Eli Lilly and Company, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04956640/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04956640> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2021-07-19" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/kras-g12c-colorectal/>, <https://onco.cc/cancers/kras-g12c-nsclc/>, <https://onco.cc/cancers/kras-g12c-pdac/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/merck/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04956640-nat-commun-2026/> .